HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction

ABSTRACT  The intrinsic immunity factor CD317 (BST-2/HM1.24/tetherin) imposes a barrier to HIV-1 release at the cell surface that can be overcome by the viral protein Vpu. Expression of Vpu results in a reduction of CD317 surface levels; however, the mechanism of this Vpu activity and its contributi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sarah Schmidt, Joëlle V. Fritz, Julia Bitzegeio, Oliver T. Fackler, Oliver T. Keppler
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2011
Materias:
Acceso en línea:https://doaj.org/article/42cca66515274df78ca2c7bcaaf17f35
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:42cca66515274df78ca2c7bcaaf17f35
record_format dspace
spelling oai:doaj.org-article:42cca66515274df78ca2c7bcaaf17f352021-11-15T15:38:50ZHIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction10.1128/mBio.00036-112150-7511https://doaj.org/article/42cca66515274df78ca2c7bcaaf17f352011-07-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00036-11https://doaj.org/toc/2150-7511ABSTRACT  The intrinsic immunity factor CD317 (BST-2/HM1.24/tetherin) imposes a barrier to HIV-1 release at the cell surface that can be overcome by the viral protein Vpu. Expression of Vpu results in a reduction of CD317 surface levels; however, the mechanism of this Vpu activity and its contribution to the virological antagonism are incompletely understood. Here, we characterized the influence of Vpu on major CD317 trafficking pathways using quantitative antibody-based endocytosis and recycling assays as well as a microinjection/microscopy-based kinetic de novo expression approach. We report that HIV-1 Vpu inhibited both the anterograde transport of newly synthesized CD317 and the recycling of CD317 to the cell surface, while the kinetics of CD317 endocytosis remained unaffected. Vpu trapped trafficking CD317 molecules at the trans-Golgi network, where the two molecules colocalized. The subversion of both CD317 transport pathways was dependent on the highly conserved diserine S52/S56 motif of Vpu; however, it did not require recruitment of the diserine motif interactor and substrate adaptor of the SCF-E3 ubiquitin ligase complex, β-TrCP. Treatment of cells with the malaria drug primaquine resulted in a CD317 trafficking defect that mirrored that induced by Vpu. Importantly, primaquine could functionally replace Vpu as a CD317 antagonist and rescue HIV-1 particle release. IMPORTANCE HIV efficiently replicates in the human host and induces the life-threatening immunodeficiency AIDS. Mammalian genomes encode proteins such as CD317 that can inhibit viral replication at the cellular level. As a countermeasure, HIV has evolved genes like vpu that can antagonize these intrinsic immunity factors. Investigating the mechanism by which Vpu overcomes the virion release restriction imposed by CD317, we find that Vpu subverts recycling and anterograde trafficking pathways of CD317, resulting in surface levels of the restriction factor insufficient to block HIV-1 spread. This describes a novel mechanism of immune evasion by HIV.Sarah SchmidtJoëlle V. FritzJulia BitzegeioOliver T. FacklerOliver T. KepplerAmerican Society for MicrobiologyarticleMicrobiologyQR1-502ENmBio, Vol 2, Iss 3 (2011)
institution DOAJ
collection DOAJ
language EN
topic Microbiology
QR1-502
spellingShingle Microbiology
QR1-502
Sarah Schmidt
Joëlle V. Fritz
Julia Bitzegeio
Oliver T. Fackler
Oliver T. Keppler
HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction
description ABSTRACT  The intrinsic immunity factor CD317 (BST-2/HM1.24/tetherin) imposes a barrier to HIV-1 release at the cell surface that can be overcome by the viral protein Vpu. Expression of Vpu results in a reduction of CD317 surface levels; however, the mechanism of this Vpu activity and its contribution to the virological antagonism are incompletely understood. Here, we characterized the influence of Vpu on major CD317 trafficking pathways using quantitative antibody-based endocytosis and recycling assays as well as a microinjection/microscopy-based kinetic de novo expression approach. We report that HIV-1 Vpu inhibited both the anterograde transport of newly synthesized CD317 and the recycling of CD317 to the cell surface, while the kinetics of CD317 endocytosis remained unaffected. Vpu trapped trafficking CD317 molecules at the trans-Golgi network, where the two molecules colocalized. The subversion of both CD317 transport pathways was dependent on the highly conserved diserine S52/S56 motif of Vpu; however, it did not require recruitment of the diserine motif interactor and substrate adaptor of the SCF-E3 ubiquitin ligase complex, β-TrCP. Treatment of cells with the malaria drug primaquine resulted in a CD317 trafficking defect that mirrored that induced by Vpu. Importantly, primaquine could functionally replace Vpu as a CD317 antagonist and rescue HIV-1 particle release. IMPORTANCE HIV efficiently replicates in the human host and induces the life-threatening immunodeficiency AIDS. Mammalian genomes encode proteins such as CD317 that can inhibit viral replication at the cellular level. As a countermeasure, HIV has evolved genes like vpu that can antagonize these intrinsic immunity factors. Investigating the mechanism by which Vpu overcomes the virion release restriction imposed by CD317, we find that Vpu subverts recycling and anterograde trafficking pathways of CD317, resulting in surface levels of the restriction factor insufficient to block HIV-1 spread. This describes a novel mechanism of immune evasion by HIV.
format article
author Sarah Schmidt
Joëlle V. Fritz
Julia Bitzegeio
Oliver T. Fackler
Oliver T. Keppler
author_facet Sarah Schmidt
Joëlle V. Fritz
Julia Bitzegeio
Oliver T. Fackler
Oliver T. Keppler
author_sort Sarah Schmidt
title HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction
title_short HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction
title_full HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction
title_fullStr HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction
title_full_unstemmed HIV-1 Vpu Blocks Recycling and Biosynthetic Transport of the Intrinsic Immunity Factor CD317/Tetherin To Overcome the Virion Release Restriction
title_sort hiv-1 vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor cd317/tetherin to overcome the virion release restriction
publisher American Society for Microbiology
publishDate 2011
url https://doaj.org/article/42cca66515274df78ca2c7bcaaf17f35
work_keys_str_mv AT sarahschmidt hiv1vpublocksrecyclingandbiosynthetictransportoftheintrinsicimmunityfactorcd317tetherintoovercomethevirionreleaserestriction
AT joellevfritz hiv1vpublocksrecyclingandbiosynthetictransportoftheintrinsicimmunityfactorcd317tetherintoovercomethevirionreleaserestriction
AT juliabitzegeio hiv1vpublocksrecyclingandbiosynthetictransportoftheintrinsicimmunityfactorcd317tetherintoovercomethevirionreleaserestriction
AT olivertfackler hiv1vpublocksrecyclingandbiosynthetictransportoftheintrinsicimmunityfactorcd317tetherintoovercomethevirionreleaserestriction
AT olivertkeppler hiv1vpublocksrecyclingandbiosynthetictransportoftheintrinsicimmunityfactorcd317tetherintoovercomethevirionreleaserestriction
_version_ 1718427822311079936